Company intelligence / Profile preview

Hemogenyx Pharmaceuticals

London, England, United Kingdomhemogenyx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Hemogenyx Pharmaceuticals has initiated a Phase I clinical trial of its lead asset HG‑CT‑1, a proprietary CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The first two patients have been treated with no adverse effects observed to date. The company continues to develop its Chimeric Bait Receptor antiviral/biodefence technology and additional pipeline assets focused on blood cancers and severe autoimmune diseases. Recent fundraising rounds have supported ongoing development.[6][8]

Therapeutic areas: OncologyHematology
Modalities: CAR-T cell therapyChimeric Bait Receptor technologyCell therapies
Industry: Biotech

Drug pipeline

5 assets

HG-CT-1

4 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Hemogenyx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemogenyx Pharmaceuticals.

Explore the full profile